Lexeo agrees acquisition of Mantle Therapeutics to expand Friedreich ataxia pipeline
Lexeo Therapeutics has agreed to acquire Mantle Therapeutics for up to $21.3 million, adding four Friedreich ataxia development programmes to its pipeline.
Lexeo will pay $8.3 million upfront with up to $13 million in additional milestone payments for assets spanning small molecules, protein replacement and RNA-based therapeutic approaches.
The transaction broadens Lexeo's rare-disease strategy beyond gene therapy and creates a multi-modality development portfolio focused on Friedreich ataxia.
Field | Content |
Alert Type | Deal |
Companies | Lexeo Therapeutics; Mantle Therapeutics |
Deal Type | Acquisition |
Asset or Company | Mantle Therapeutics and four Friedreich ataxia programmes |
Therapy Area(s) | Rare disease; neurology; Friedreich ataxia |
Technology or Modality | Small molecules; protein replacement; RNA-based therapies |
Deal Value | US$8.3 million upfront plus up to US$13 million in milestone payments; total potential consideration US$21.3 million |
Geography | United States |
What Happened | Lexeo Therapeutics entered an agreement to acquire Mantle Therapeutics and its four Friedreich ataxia development programmes. |
Why It Matters | The acquisition expands Lexeo's rare-disease pipeline across several therapeutic modalities and deepens its focus on Friedreich ataxia. |
Supporting Context | Mantle's programmes span small-molecule, protein-replacement and RNA-based approaches rather than relying on a single therapeutic technology. |
Strategic Rationale | Lexeo gains a broader platform of Friedreich ataxia assets that complements its existing genetic-medicine expertise. |
Potential Impact | A diversified pipeline could increase the chances of identifying effective treatments across different biological mechanisms involved in Friedreich ataxia. |
Key Takeaway | Lexeo is acquiring Mantle Therapeutics for up to US$21.3 million to add four Friedreich ataxia programmes. |
What to Watch | Transaction completion, prioritisation of the acquired programmes and advancement toward clinical development. |
Primary Source | Lexeo Therapeutics |
Relevant Date | 22 September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comments